	US 12,351,799 B2
	S. pyogenes CAS9 mutant genes and polypeptides encoded by same
Christopher Anthony Vakulskas, North Liberty, IA (US); Michael Allen Collingwood, North Liberty, IA (US); Garrett Richard Rettig, Coralville, IA (US); and Mark Aaron Behlke, Coralville, IA (US)
Assigned to INTEGRATED DNA TECHNOLOGIES, INC., Coralville, IA (US)
Filed by INTEGRATED DNA TECHNOLOGIES, INC., Coralville, IA (US)
Filed on Dec. 5, 2024, as Appl. No. 18/970,552.
Application 16/931,889 is a division of application No. 15/729,491, filed on Oct. 10, 2017, granted, now 10,717,978, issued on Jul. 21, 2020.
Application 18/970,552 is a continuation of application No. 17/870,190, filed on Jul. 21, 2022, granted, now 12,168,765.
Application 17/870,190 is a continuation of application No. 16/931,889, filed on Jul. 17, 2020, granted, now 11,427,818, issued on Aug. 30, 2022.
Claims priority of provisional application 62/405,601, filed on Oct. 7, 2016.
Prior Publication US 2025/0109395 A1, Apr. 3, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/11 (2006.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01); C12N 15/90 (2006.01)

CPC C12N 15/11 (2013.01) [C12N 9/22 (2013.01); C12N 15/902 (2013.01); C12N 15/113 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)]

9 Claims

1. An isolated mutant Cas9 protein, comprising a single R691A substitution relative to the wild-type Cas9 amino acid sequence of SEQ ID NO: 5.